Clinical Trials Details

EA9161 (Leukemia)

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Categories

  • Cancers and Other Neoplasms